Cancer Genetics Inc. (CGIX)’s Financial Results Comparing With NeoGenomics Inc. (NASDAQ:NEO)

Cancer Genetics Inc. (NASDAQ:CGIX) and NeoGenomics Inc. (NASDAQ:NEO) have been rivals in the Medical Laboratories & Research for quite some time. Below is a review of each business including various aspects such as analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cancer Genetics Inc. 28.17M 0.48 24.51M -0.29 0.00
NeoGenomics Inc. 276.74M 6.69 6.09M 0.06 299.84

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for Cancer Genetics Inc. and NeoGenomics Inc.


Table 2 hightlights the net margins, return on equity and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Cancer Genetics Inc. -87.01% -133.7% -54.5%
NeoGenomics Inc. 2.20% -0.7% -0.4%

Risk & Volatility

Cancer Genetics Inc. has a 1.21 beta, while its volatility is 21.00% which is more volatile than S&P 500. In other hand, NeoGenomics Inc. has beta of 0.94 which is 6.00% less volatile than S&P 500.


Cancer Genetics Inc.’s Current Ratio and Quick Ratio are 0.5 and 0.5 respectively. The Current Ratio and Quick Ratio of its competitor NeoGenomics Inc. are 4.1 and 4 respectively. NeoGenomics Inc. therefore has a better chance of paying off short and long-term obligations compared to Cancer Genetics Inc.

Analyst Ratings

The Ratings and Recommendations for Cancer Genetics Inc. and NeoGenomics Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Cancer Genetics Inc. 0 0 0 0.00
NeoGenomics Inc. 0 0 4 3.00

Meanwhile, NeoGenomics Inc.’s average target price is $21, while its potential upside is 7.31%.

Institutional and Insider Ownership

Cancer Genetics Inc. and NeoGenomics Inc. has shares held by institutional investors as follows: 6% and 78%. Insiders held roughly 13.2% of Cancer Genetics Inc.’s shares. Competitively, NeoGenomics Inc. has 0.6% of it’s share held by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Cancer Genetics Inc. -3.77% 10.56% -8.87% -71.54% -84.46% 10.74%
NeoGenomics Inc. -0.57% 15.46% 14.91% 38.66% 126.03% 52.18%

For the past year Cancer Genetics Inc. has weaker performance than NeoGenomics Inc.


NeoGenomics Inc. beats on 12 of the 12 factors Cancer Genetics Inc.

Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, India, and China. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. The companyÂ’s clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management. Its biopharma services offer companies with customized solutions for patient stratification and treatment selection through a suite of molecular- and biomarker-based testing services, customized assay development, and trial design consultation. The companyÂ’s discovery services provide the tools and testing methods for companies and researchers to identify new molecular-based biomarkers for disease. It serves hospitals, cancer centers, clinics, academic institutions, and government-sponsored research institutions, as well as pharmaceutical and biotech companies performing clinical trials. The company collaborates with oncology centers and community-based hospitals to develop its proprietary diagnostic tests. Cancer Genetics, Inc. was founded in 1999 and is based in Rutherford, New Jersey.

NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services that focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clientsÂ’ oncology programs, as well as acts as a reference laboratory supplying anatomic pathology testing services. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.